Stifel analyst Daniel Arias lowered the firm’s price target on Repligen to $210 from $225 and keeps a Buy rating on the shares. There "appear to be pockets of encouraging demand at the moment," but within an overall business that is "clearly still finding its footing," says the analyst, who adds that management’s re-calibrated outlook "should reflect the current state of the market."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RGEN:
- Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
- Repligen sees lowers 2023 adjusted EPS $2.35-$2.42 from $2.61-$2.69
- Repligen reports Q1 adjusted EPS 64c, consensus 59c
- RGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Repligen to Report First Quarter 2023 Financial Results